NDAINJECTIONINJECTABLE
Approved
May 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ORAVERSE (phentolamine mesylate) by Septodont is soft-tissue anesthesia and the associated functional deficits is not fully understood. First approved in 2008.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORAVERSE (phentolamine mesylate) is an injectable alpha-adrenergic antagonist that reverses the effects of local anesthetics containing vasoconstrictors, particularly lidocaine with epinephrine. It works by blocking alpha-adrenergic receptors on vascular smooth muscle, promoting vasodilatation and accelerating the reversal of soft-tissue anesthesia and associated functional deficits. The drug is indicated for use in dental and oral surgical procedures where rapid anesthesia reversal is desired.
LOE Approaching
Niche specialty product with modest market penetration and moderate competitive pressure; teams likely focused on maintaining market position as patent expiration approaches.
Mechanism of Action
soft-tissue anesthesia and the associated functional deficits is not fully understood. Phentolamine mesylate, the active ingredient in OraVerse, produces an alpha-adrenergic block of relatively short duration resulting in vasodilatation when applied to vascular smooth muscle. In an animal model,…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ORAVERSE represents a specialized career opportunity in a niche dental/oral specialty market with limited growth trajectory but established market position. Roles are concentrated in commercial and sales functions rather than clinical development, offering stability but modest advancement potential as the product approaches LOE.
Brand Manager
Worked on ORAVERSE at Septodont? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.